Kanion Group

Kanion Group

Xiao Wei established the Lianyungang-headquartered group in 1999 as an extension of his pharmaceutical operations. The wealth originates from Jiangsu Kanion Pharmaceutical, a major producer of traditional Chinese medicine and biomedical products. Kanion Group functions as the private investment vehicle for Xiao Wei and his family, with his relative Jun Guo Xiao and associate Xin Jian Xu holding director roles in the group holding company. The portfolio mixes direct operating businesses with passive investments. Core holdings remain concentrated in healthcare, through the flagship pharmaceutical entity. Adjacent to this, the group has built an ecological agriculture division, an international trade operation, and a hospitality and real estate portfolio. A mixed-use commercial complex in Huaihua's Chengdong New Area represents a significant property commitment, while the broader Kanion Group Property Portfolio spans multiple Chinese locations. The group also manages a collection of intellectual property, including blockchain and NFT-related assets and a Hong Kong-registered BYURSIDE trademark. Team size and total capital deployment remain private. The organization operates primarily from Jiangsu province, with business interests reaching other Chinese regions and Hong Kong. Xiao Wei participates in policy-focused networks including the BRI Think Tank, signaling an interest in internationalization aligned with China's Belt and Road Initiative. The group's structure integrates the holding company's strategic and financial oversight with the operating scale of a major pharmaceutical enterprise, a configuration that gives the family office both cash flow from operations and the capacity for independent investment decisions. The structural differentiator is the tight integration with a single, substantial operating company. Unlike offices managing liquidated wealth, Kanion Group's capital comes from an ongoing enterprise whose research and manufacturing base in traditional Chinese medicine provides a direct lens into biotech and healthcare opportunities. The presence of family members and long-term business partners on the board suggests a succession structure already in motion, with governance shared across the founder's inner circle rather than professionalized third-party managers.